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with platelet-rich plasmaFederica Jiritano, MD, Giuseppe Filiberto Serraino, MD, Lucia Cristodoro, MD, and
Attilio Renzulli, MD, PhD, Catanzaro, ItalyThe contemporary trend toward left ventricular assist
device (LVAD) implantation as a definitive treatment for
end-stage heart failure has yielded a valid alternative for
those patients who are not suitable candidates for heart
transplantation and whose conditions are refractory to
medical treatment.1 The long-term use of such devices,
however, has brought into the spotlight a number of compli-
cations related to the interaction between the human body
and the mechanical component. One of these is driveline
infection, which in the worst-case scenario could lead to
sepsis, forced explantation of the LVAD, or even death.2
The treatment is challenging and sometimes delayed be-
cause the problem occurs in patients already out in in the
community. Vacuum-assisted closure (VAC) therapy, tar-
geted antimicrobial therapy, and other advanced dressings
have been proposed as valid treatments for driveline infec-
tions.3 We report 2 cases in which the previously mentioned
measures failed to cure the infection, whereas continued
topical application of autologous platelet-rich plasma
(PRP) over the wound for about 2 weeks resolved the
infection and closed the exit wound.CLINICAL SUMMARIES
Patient 1
A 49-year-old man with end-stage cardiac failure
(New York Heart Association functional class IV) was
admitted with ascites and orthopnea. Five days after the hos-
pital admission, the patient had acute abdominal pain, proc-
torrhagia, and anemia, necessitating urgent laparotomy.Ischemic colitis involving the rectum was found; it was re-
sected, and a left colostomy was performed. Hemodynamic
conditions improved steadily, and the patient was extubated
on the third postoperative day. However he developed renal
failure requiring hemodialysis. After 10 days, theHeartWare
VAD system (HeartWare International, Inc, Framingham,
Mass) was implanted. Seven days later, the skin around
the exit site of the abdominal cable became erythematous
with serum and purulent discharge.Escherichia coliwas iso-
lated, and intravenous treatment with ciprofloxacin was
started on the basis of the antibiogram. After 1 week of an-
tibiotic therapy, the infection had not improved. The exit site
wound was then dressed every 3 days for a total of 5 times
with autologous PRP until the 28th postoperative day,
when it appeared completely closed with good tissue heal-
ing. Chronic kidney failure necessitating daily dialysis per-
sisted. On the 32nd postoperative day, the patient had acute
cardiovascular and respiratory failure develop, necessitating
mechanical ventilation and maximum inotropic support.
Cardiac tamponade was diagnosed, and 1.5 L of blood-
stained fluid was drained. The patient’s cardiac function re-
covered, but he could not be weaned from mechanical
ventilation and dialysis. He died on the 50th postoperative
day of multiple organ failure. No signs of skin infection
were found around the driveline.Patient 2
A 50-year-old man who was obese (body mass index 36
kg/m2) and had diabetes and dilated cardiomyopathy was
admitted to hospital for end-stage cardiac failure. The pa-
tient underwent LVAD (HeartWare) implantation through
a median sternotomy. His postoperative course was un-
eventful, and he was discharged on the 15th postoperative
day. On the 30th postoperative day, a purulent and smelly
discharge developed at the abdominal cable exit site. Swabs
were sent for culture, and multiresistant Acinetobacter
baumannii (sensitive to colistimethate sodium [INN colis-
tin]) and Staphylococcus aureus (sensitive to linezolid)
were isolated. Intravenous antibiotic treatment targetedrdiovascular Surgery c Volume 145, Number 6 e69
FIGURE 1. Photographs of patient 2. A, Infection of the abdominal driveline exit site despite antibiotic and vacuum-assisted closure therapy. B, Autol-
ogous platelet-rich plasma application over the infected wound. C, At 4-week follow-up after placement of the platelet-rich plasma dressing, good wound
healing can be seen.
Case Reportsaccording to the antibiogram was started, together with lo-
cal wound dressing with chlorhexidine gluconate. After 2
weeks of antibiotic treatment, the infection appeared worse,
and VAC therapy was started. After a week of combined
treatment, we did not observe any favorable response.
VAC therapy was switched to local application of autolo-
gous PRP. The application and wound dressing were
repeated every 3 days for 2 weeks, with the patient remain-
ing in the community. After the treatment, the infection
disappeared with good healing of the wound (Figure 1).DISCUSSION
Driveline infection is a life-threatening LVAD complica-
tion that can lead to device removal, and it remains the
foremost cause of death among patients with long-term me-
chanical assistance.2 Several therapeutic approaches have
been proposed through the years to treat LVAD driveline in-
fections, with controversial results.3,4 Some authors have
proposed intravenous antibiotic therapy against germs,
driveline immobilization, and aggressive surgical excision
of the involved exit site.5 Despite aggressive therapy, how-
ever, cases of antibiotic refractory driveline infections are
still reported.
In the early 1990s, PRP was proposed in the treatment of
postsurgical infections, with good clinical results.6 During
the inflammatory phase of tissue healing, activated platelets
release specific growth factors. These include platelet-
derived growth factor, transforming growth factor-b, vascu-
lar endothelial growth factor, and epithelial growth factor.
Platelet growth factor—together with other growth factors
and cytokines—helps to regulate the early migration of
cells to the injury site, cell mitosis, angiogenesis, granula-
tion tissue formation, and bone regeneration.6 Furthermore,e70 The Journal of Thoracic and Cardiovascular SurgBielecki and colleagues7 showed that PRP inhibits the
growth of S aureus and E coli in vitro.7 The antimicrobial
action of white blood cells and platelets, both found in
PRP, could reduce the development of driveline infection.
CONCLUSIONS
In our 2 cases, the topical application of autologous PRP
helped in the treatment of abdominal driveline infection
refractory to antibiotic treatment alone. The clinical cases
here reported are the only cases with abdominal driveline
infection observed in our institution. This is the first report
to our knowledge of PRP use in the successful treatment
of abdominal driveline infection refractory to antibiotic
treatment alone.References
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